• Busca persones
• Intranet

Clínica aplicada en neoplàsies hematològiques Beatriz Bellosillo

Publicacions 2023 (29)

• Delamare M, le Roy A, Pacault M, Schmitt L, Garrec C, Maaziz N, Myllykoski M, Rimbert A, Karaghiannis V, Aral B, Catherwood M, Airaud F, Mansour-Hendili L, Hoogewijs D, Peroni E, Idriss S, Lesieur V, Caillaud A, Si-Tayeb K, Chariau C, Gaignerie A, Rab M, Haferlach T, Meggendorfer M, Bézieau S, Benetti A, Casadevall N, Hirsch P, Rose C, Wemeau M, Galacteros F, Cassinat B, Bellosillo B, Bento C, van Wijk R, Petrides PE, Randi ML, McMullin MF, Koivunen P, Girodon F, Gardie B, ECYT-3 consortium. Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosis. Haematologica (online) 2023: (en Premsa).
• Albiol N^*, Lynton-Pons E, Aso O, Moga E, Vidal S, Gomez-Perez L, Santiago JA, Triquell M, Roch N, Lazaro E, González I, López-Contreras J, Esquirol A, Sierra J, Martino R, García-Cadenas I^*. mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect. Leuk Res 2023; 132: (en Premsa).
• Muntañola A^*, Villalobos MT, González-Villambrosia S, Rodriguez-Salazar MJ, Jiménez-Ubieto A, Bastidas-Mora G, Córdoba R, Infante M, Vidal MJ, Díaz FJ, Baile M, Bastos-Oreiro M, Panizo C, Sancho JM, Navarro B, Garcia T, Escoda L, Abrisqueta P, Terol MJ, de Campo R, Mozas P, López-Guillermo A, Salar A^*, Montalbán C, GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study. Br J Haematol 2023: (en Premsa).
• Álvarez-López P^*, Bellosillo B, Colom F, Longarón R, Barrera M, Fernández-Ibarrondo L, Toll A, Gines JM, de la Torre R, Pérez V, Robledo P. Y-chromosome in the olfactory neuroepithelium as a potential biomarker of depression in women with male offspring: an exploratory study. Mol Cell Biochem 2023: (en Premsa).
• Martin A^*, Baile M, Rodríguez G, Dlouhy I, Sancho JM, Jarque I, González-Barca E, Salar A, Espeso M, Grande C, Bergua J, Montes-Moreno S, Redondo A, Enjuanes A, Campo E, López-Guillermo A, Caballero D. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO. Br J Haematol 2023: (en Premsa).
• González-Farré M^*, Gibert J, Santiago P, Menéndez S, Montzonis X, Olivares F, Riera X, López D, Torner A, Casado B, Bellosillo B, Lloveras B, Casadevall D, Rovira A, Servitja S, Albanell J, Vázquez I, Comerma L. Characterization and Spatial Distribution of the Immune Cell Infiltrate in Triple-Negative Breast Cancer: A Novel Classification based on Plasma Cells and CD8+ T cells. Hum Pathol 2023: (en Premsa).
• González-Farré M^*, Gibert J, Santiago P, Santos J, García-Moreno P, Massó J, Bellosillo B, Lloveras B, Albanell J, Vazquez I, Comerma L. Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer. Virchows Arch 2023: (en Premsa).
• Calvo X, Roman-Bravo D, Garcia N, Fernández-Rodríguez C, Rial A, Garcia-Avila S, López-Cadenas F, Salido M, Ferrer A, Arenillas L. Sex-associated differences in genomic profile of chronic myelomonocytic leukemia involving differential representation of SRSF2 gene mutation. Int J Lab Hematol . 2023: (en Premsa).
• Montesdeoca S, Garcia N, Calvo X, Arenillas L, Roman-Bravo D, Fernández-Rodríguez MC, Navarro R, Costan-Medina B, Vela MC, Camacho L, Abella E, Colomo L, Salido M, Puiggros A, Florensa L, Espinet B, Bellosillo B, Ferrer A^*. Leukemic Involvement Is a Common Feature in Waldenström Macroglobulinemia at Diagnosis. Cancers 2023; 15(16): 4152.
• Pérez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Perez-Lopez R, Ruiz-Nuño C, De Las Heras N, Mora-Casterá E, López-Marín J, Segura-Díaz A, Gómez V, Vélez P, Sierra-Pacho M, Vera-Goñi JA, Moreno-Vega M, Álvarez-Larran A, Cortés M, Pérez-Encinas M, Carrascosa-Mastell P, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila E, Cervero C, Cuevas B, Villalón-Blanco L, de Paz R, Paz-Coll A, Fernández MJ, Felipe-Casado L, Alonso JM, Anguita-Arance MM, Salamanca-Cuenca A, Jiménez-Velasco A, Osorio-Prendes S, Santaliestra M, Lis-Chulvi MJ, Hernández-Boluda JC, García-Gutiérrez V^*. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors. Cancers 2023; 15(4): 1045.
• Rocha P, Rodrigo M, Moliner L, Menéndez S, Masfarre-Pinto L, Navarro-Gorro N, del Rey-Vergara R, Galindo M, Taus A, Giner M, Sánchez I, Rodríguez-Fuster A, Aguiló R, Chalela R, Sánchez-Font A, Belda J, Curull V, Pijuan L, Casadevall D, Clavé S, Bellosillo B, Perera J, Comerma L, Arriola E^*. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer. Lung Cancer 2023; 181: 107257.
• Valero-Tena E, Roca-Espiau M, Verdú-Díaz J, Díaz-Manera J, Andrade-Campos M, Giraldo P^*. Advantages of digital technology in the assessment of bone marrow involvement in Gaucher's disease. Front Med (Lausanne) . 2023; 10: 1098472 (Acceptat).
• Oñate G, Pratcorona M, Garrido A, Artigas-Baleri A, Bataller A, Tormo M, Arnan M, Vives S, Coll R, Salamero O, Vall-Llovera F, Sampol A, Garcia A, Cervera M, Garcia-Avila S, Bargay J, Ortín X, Nomdedeu JF, Esteve J, Sierra J^*, Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM). Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort. Blood Cancer J 2023; 13(1): 69.
• Martínez-Bosch N, Vilariño N, Alameda F, Mojal S, Arumí M, Carrato C, Aldecoa I, Ribalta T, Vidal N, Bellosillo B, Menéndez S, Del Barco S, Gallego O, Pineda E, Lopez-Martos R, Hernández A, Mesia C, Esteve-Codina A, de la Iglesia N, Balañá C, Martínez-García M^*, Navarro P^*. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells 2023; 12(6): 843.
• Rodriguez JJ, Fernández Rodríguez C, Bento L, Diez-Feijoo R, Pinzon SF, Gibert J, Fernández-Ibarrondo L, Lafuente M, Ferrer A, Sánchez-González B, Gimeno E, Sainz J, Ramos-Asensio R, Garcia JF, Colomo L, Bellosillo B, Gutiérrez A, Salar A^*. Evaluation of four prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Blood Adv 2023; 7(8): 1606-1614.
  Cites:2
  Cites:2
• Canales MA^*, Buchholz TA, Bortolini JAP, Fogliatto LM, Ishikawa T, Izutsu K, Salar A, Sharman JP, Klingbiel D, Pokala S, Vorozheikina E, Trask P, Parreira J, Hübel K. Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis. Hemasphere . 2023; 7(4): e860 (Acceptat).
• Ródenas-Quiñonero I, Chen-Liang T, Martín-Santos T, Salar A, Fernandez-González M, Celades C, Navarro JT, Martínez-Garcia AB, Andreu R, Balaguer A, Martin A, Baile M, López-Jiménez J, Marquet-Palomanes J, Teruel AI, Terol MJ, Benet C, Frutos L, Navarro JL, Uña J, Suarez-Piñera M, Cortes M, Contreras J, Ruiz C, Tamayo P, Mucientes J, Sopena-Novales P, Reguilón-Gallego L, Sánchez-Blanco JJ, Pérez-Ceballos E, Jerez A, Ortuño FJ^*. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study. Cancer Med 2023; 12(6): 6536-6546.
  Cites:1
  Cites:1
• Giraldo P^*, Andrade-Campos M, Morales M, SEGA (SEguimiento del paciente de GAucher, Gaucher patient follow-up) Group. Recommendations on the follow-up of patients with Gaucher disease in Spain: Results from a Delphi survey. JIMD Rep 2023; 64(1): 90-103 (Acceptat).
• Muntañola A^*, Mozas P, Mercadal S, Huguet M, Bobillo S, Bastos-Oreiro M, Jiménez-Ubieto A, Rovira J, Rivero A, Tolosa C, Luizaga L, González-de-Villambrosia S, Novelli S, Caballero D, Salar A, Alonso-Álvarez S, Magnano L, Gutiérrez NC, Sancho JM, López-Guillermo A, GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome. Br J Haematol 2023; 200(3): 306-314.
  Cites:1
  Cites:1
• Muntañola A, Arguiñano-Pérez JM, Dávila J, González-de-Villambrosia S, Carpio C, Jiménez-Ubieto A, Salar A^*, GELTAMO (Grupo español de linfomas y trasplante de médula ósea). Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting. CTS-Clin. Transl. Sci. 2023; 16(2): 305-312.
• González-López TJ^*, Bárez A, Bernardo-Gutiérrez A, Bernat S, Canaro-Hhirnyk M, Entrena-Ureña L, Fernández-Fuertes F, Guinea JM, Jiménez-Bárcenas R, Pascual-Izquierdo C, Sánchez-González B, Jarque I. Recommendations on the Management of Patients with Immune Thrombocytopenia (ITP) in the Context of SARS-CoV-2 Infection and Vaccination: Consensus Guidelines from a Spanish ITP Expert Group. Infect Dis Ther . 2023; 12(2): 303-315.
  Cites:2
  Cites:2
• Canillas L, Pelegrina A, Álvarez-García JC, Colominas-González E, Salar A, Aguilera L, Burdío F, Montes A, Grau S, Grande L, Carrion JA^*. Clinical Guideline on Perioperative Management of Patients with Advanced Chronic Liver Disease. Life (Basel) . 2023; 13(1): 132.
  Cites:2
  Cites:2
• Montero MM, Hardy-Werbin M, Gonzalez-Gallardo S, Torres E, Rueda-Miret R, Hannet I, Kirk JT, Yager TD, Navalkar K, Arenas-Miras MM, Arietta-Aldea I, Espinosa S, Gómez J, Gómez-Zorrilla S, Güerri-Fernández R, Sánchez F, Lopez Montesinos I, Pelegrin I, Sendra E, Sorli L, Villar-García J, Bellosillo B^*, Horcajada JP. Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients. Sci Rep 2023; 13(1): 944.
  Cites:1
  Cites:1
• Vidal J, Fernández-Rodríguez MC, Casadevall D, García-Alfonso P, Paez D, Guix M, Alonso V, Cano MT, Santos C, Durán G, Élez E, Manzano JL, García-Carbonero R, Ferreiro-Monteagudo R, Losa F, Pineda E, Sastre J, Rivera F, Bellosillo B, Tabernero J, Aranda E, Salazar R, Montagut C^*. Liquid biopsy detects early molecular response and predicts benefit to first-line chemotherapy plus cetuximab in metastatic colorectal cancer: PLATFORM-B study. Clin Cancer Res 2023; 29(2): 379-388.
  Cites:4
  Cites:4
• Diez-Feijoo R, Fernández-Rodríguez MC, Lafuente M, Garcia N, Ferrer A, Colomo L, Salido M, Salar A^*. First description of the t(3;17)(q27;q21)/IGF2BP2::LSM12 translocation in marginal zone lymphoma. Blood Adv 2023; 7(1): 162-166.
• Mosquera-Orgueira A^*, Pérez-Encinas M, Hernández-Sánchez A, González-Martínez T, Arellano-Rodrigo E, Martínez-Elicegui J, Villaverde-Ramiro Á, Raya JM, Ayala R, Ferrer-Marín F, Fox ML, Vélez P, Mora E, Xicoy B, Mata-Vazquez MI, García-Fortes M, Angona A, Cuevas B, Senín A, Ramírez-Payer Á, Ramírez MJ, Perez-Lopez R, González-de-Villambrosia S, Martínez-Valverde C, Gómez-Casares MT, García-Hernández C, Gasior M, Bellosillo B, Steegmann JL, Álvarez-Larran A, Hernández-Rivas JM, Hernández-Boluda JC^*. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis. Hemasphere 2023; 7(1): e818 (Acceptat).
  Cites:6
  Cites:6
• Barba P^*, Morgades M, Montesinos P, González-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, García-Cadenas I, Queipo de Llano MP, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, García-Boyero R, Novo A, Hernández-Rivas JM, Cladera A, Martínez-Sánchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM. Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols. Hemasphere . 2023; 7(1): e810. (Acceptat).
• Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruiz-Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba-Rodríguez J, Espinosa E, Minisini AM, Quiroga V, Santaballa-Bertran A, Mina L, Bellosillo B, Rojo F, Menéndez S, Sampayo M, Popa C, Malfettone A, Cortés J, Llombart-Cussac A^*. Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. Clin Cancer Res 2023; 29(1): 67-80.
  Cites:7
  Cites:7
• Muniesa C, Gallardo F, García-Doval I, Estrach MT, Combalia A, Morillo-Andújar M, de la Cruz F, Machan S, Moya-Martínez C, Rovira R, Sánchez-González B, Acebo E, Amutio E, Peñate Y, Losada-Castillo MC, García-Muret MP, Iznardo H, Román-Curto C, Cañueto J, Fernandez de Misa R, Flórez A, Izu R, Torres-Navarro I, Zayas A, Pérez-Paredes G, Blanes M, Yanguas JI, Pérez-Ferriols A, Callejas-Charavia M, Ortiz-Romero P.L, Pérez-Gil A, Prieto-Torres L, González-Barca E, Servitje O^*. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. J Eur Acad Dermatol Venereol 2023; 37(1): 57-64.
  Cites:2
  Cites:2